Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 4

Status

Terminated 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Sarcoma 1Breast 1

Conditions

Sarcoma 1Non-Squamous Non-Small Cell Lung Cancer 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × RG-1507 monoclonal antibody × Clear all
NCT00642941 2021-02-03

A Study of R1507 in Participants With Recurrent or Refractory Sarcoma

Hoffmann-La Roche

Phase 2 Terminated
317 enrolled 27 charts
Sarcoma

Sarcoma

NCT00760929 2021-01-05

A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).

Hoffmann-La Roche

Phase 2 Terminated
171 enrolled 17 charts
Thoracic

Non-Squamous Non-Small Cell Lung Cancer

NCT00796107 2020-11-13

A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer

Hoffmann-La Roche

Phase 2 Terminated
6 enrolled 5 charts
Breast

Breast Neoplasms

NCT00773383 2013-06-24

A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.

Hoffmann-La Roche

Phase 2 Terminated
35 enrolled 9 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡